_if you need more than one keyword, modify and separate by underscore _
the list of search keywords can be up to 50 characters long
if you modify the keywords, press enter within the field to confirm the new search key
Tag: astrazeneca
Bibliography items where occurs: 5
- The Minimum Information about CLinical Artificial Intelligence Checklist for Generative Modeling Research (MI-CLAIM-GEN) / 2403.02558 / ISBN:https://doi.org/10.48550/arXiv.2403.02558 / Published by ArXiv / on (web) Publishing site
- Disclosures
- The Narrow Depth and Breadth of Corporate Responsible AI Research / 2405.12193 / ISBN:https://doi.org/10.48550/arXiv.2405.12193 / Published by ArXiv / on (web) Publishing site
- S2 Additional Analyses on Linguistic Analysis
- Challenges and Best Practices in Corporate AI Governance:Lessons from the Biopharmaceutical Industry / 2407.05339 / ISBN:https://doi.org/10.48550/arXiv.2407.05339 / Published by ArXiv / on (web) Publishing site
- Abstract
1 Introduction | The need for corporate AI governance
2 Case study | AstraZeneca’s AI governance journey
3 Practical implementation challenges | What to be prepared for?
4 Discussion | Best practices and lessons learned
5 Concluding remarks | Upfront investments vs. long-term benefits
7 Conflict of Interest - Operationalising AI governance through ethics-based auditing: An industry case study / 2407.06232 / Published by ArXiv / on (web) Publishing site
- Abstract
1. Introduction
3. AstraZeneca and AI governance
4. An ‘ethics-based’ AI audit
5. Methodology: An industry case study
6. Lessons learned from AstraZeneca’s 2021 AI audit
7. Limitations
8. Conclusions
REFERENCES
APPENDIX 1 - Auditing of AI: Legal, Ethical and Technical Approaches / 2407.06235 / Published by ArXiv / on (web) Publishing site
- 4 Auditing of AI’s multidisciplinary foundations